Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YAZ 24/4 versus Mercilon 21/7 for hormone withdrawal-associated symptoms in oral contraceptive users
2009-014911-11Phase 3Completed
- Sponsor
- Bayer
- Start
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial comparing YAZ 24/4 with Mercilon 21/7 (2 arms). Primary endpoint: Primary efficacy endpoint. Started Jan 2010; status: completed.
02
Drugs
ethinyl estradiol + drospirenoneethinyl estradiol + desogestrel
Beyond the preview
Go deeper on 2009-014911-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014911-11.